Impactful Data in TD That Can Guide Treatment Decisions

Program Introduction

This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

TD Epidemiology, Healthcare Use, and the Educational Needs of TD Healthcare Providers

Incidence and Prevalence of TD: US Data

TD Global Prevalence With SGAs

TD Global Prevalence With SGAs (cont)

Healthcare Use and Costs for Patients With TD

Educational Needs of Physicians Treating TD

Summary

How TD Affects Quality of Life and Function

Study on How TD Affects QoL: Design

Study on How TD Affects QoL: Interim Results

Brief History of TD

Effects of TD on Daily Life

Treating TD Symptoms

Managing TD From a Nursing Perspective

TD From an Historical Perspective and Strategies for Improved Management With Currently Approved VMAT2 Inhibitors

Where Does TD Fit In?

5 Steps to Improving TD Management

Deutetrabenazine in AIM-TD: NNT and NNH

Deutetrabenazine AEs

Valbenazine in KINECT3: NNT

Valbenazine in KINECT3: NNH and AEs

Conclusions

VMAT2 Inhibitors

Open-Label Extension Study on Long-Term Safety of Deutetrabenazine

Pooled Analysis on Long-Term Safety of Valbenazine

Pooled Analysis on Cardiovascular Safety of Valbenazine

Establishing an MCID for AIMS Score Change

Risk Factors for TD and Efficacy of VMAT2 Inhibitors

Risk Factors for TD

Valbenazine for TD in Schizophrenia and Schizoaffective Disorders: KINECT3 Findings

Valbenazine for TD in Mood Disorders: KINECT3 Findings

Systematic Review of VMAT2 Inhibitors in TD

Abbreviations

Abbreviations (cont)